PCI Biotech: Presentation of fimaChem for bile duct cancer at IPA masterclass series
November 08, 2021 05:15 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 8 November 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the coordinating principal investigator for the RELEASE trial, Prof. Dr. Jörg...
PCI Biotech first quarter 2021 interim results
May 07, 2021 01:00 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 7 May 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q1 2021 results. Please find enclosed the report and presentation. ...
OliX Pharmaceuticals and PCI Biotech announce a collaboration to combine OliX asiRNA and PCI Biotech fimaNAc technologies
May 05, 2021 05:00 ET
|
PCI Biotech Holding ASA
Suwon, South Korea and Oslo, Norway, May, 5th 2021 – OliX Pharmaceuticals Inc. (KOSDAQ: 226950) a leading developer of RNAi therapeutics, and PCI Biotech (OSE: PCIB), a cancer focused...
PCI Biotech fourth quarter and preliminary full year 2020 results
February 24, 2021 01:00 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 24 February 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q4 and preliminary full year 2020 results. Please find enclosed the...
PCI Biotech - release of the RNA Therapeutics Virtual Conference presentation
February 10, 2021 02:31 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 10 February 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today released...
PCI Biotech: US patent for the vaccine technology (fimaVacc) with a new important class of adjuvants
March 26, 2020 04:12 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 26 March 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces that the U.S. Patent and Trademark Office (USPTO) has informed the company that a...
PCI Biotech's fourth quarter and preliminary 2019 results
February 26, 2020 01:00 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 26 February 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim fourth quarter and preliminary 2019 results. Please find enclosed the...